Lapatinib in combination with paclitaxel for the first-line treatment of metastatic breast cancer which over-expresses ErbB2 (HER2) receptor
Status Suspended
Decision Selected
Process STA pre-2018
Referral date 01 November 2011
Topic area
  • Cancer

Scoped as part of Batch 20

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Communications manager: TBC
Executive Lead: TBC
Project manager: TBC
Technical Lead: TBC


Key events during the development of the guidance:

Date Update
21 March 2012

The Institute has now been informed by the manufacturer that it has withdrawn its application for a centralised marketing authorisation for lapatinib in combination with paclitaxel, which was based on the results of the EGF104535 study.

Further information is available here.

Therefore, NICE has decided to suspend this appraisal on its current work programme.
As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.

For further information on our processes and methods, please see our CHTE processes and methods manual